Articles related to LEUKEMIA
Early Intervention in Asymptomatic Chronic Lymphocytic Leukemia
For the estimated 21,000 patients who will receive a diagnosis of chronic lymphocytic leukemia (CLL), 20% of them will have early-stage disease. Unfortunately, that 20% will not be offered treatment, as the current management of these patients follows a “watch-and-wait” paradigm. However, with the advent of better prognostic tools to identify patients at high risk, in addition to the recent approval of several novel oral agents with impressive efficacy, re-examining this approach now seems prudent.
Hematology March 9th 2021
Highlights in Chronic Lymphocytic Leukemia From the 62nd ASH Annual Meeting and Exposition
This article presents a review and commentary of selected presentations from the all-virtual 62nd American Society of Hematology (ASH) Meeting and Exposition, which took place in December 2020. Coverage includes safety and efficacy results in trials of acalabrutinib, venetoclax, obinutuzumab, rituximab, LOXO-305, idelalisib, bendamustine, umbralisib, ublituximab, chlorambucil, lisocabtagene maraleucel, and others.
Hematology February 16th 2021
Choosing Between Novel Agents and Chemoimmunotherapy in CLL
From the pages of Clinical Advances in Hematology & Oncology comes this Q&A with Jennifer A. Woyach, MD, a Professor of Medicine in the Division of Hematology at the Ohio State University Comprehensive Cancer Center. Dr. Woyach provides extensive commentary on BTK, BCL2, and PI3K inhibitors, FCR usage, and the importance of clinical trials when treating patients with CLL.
Hematology January 5th 2021
Evolving Strategies for the Management of Core-Binding Factor Acute Myeloid Leukemia (AML)
In this Q&A, Dr. Gautam Borthakur from the University of Texas MD Anderson Cancer Center talks with Clinical Advances in Hematology & Oncology about the goals, treatment options (including tailored treatment), differences in de novo vs. therapy-related, and other suggestions in patients with core-binding factor acute myeloid leukemia (AML).
Hematology November 24th 2020
Three-Drug Combination Induces Deep Remission in Treatment-Naive, R/R CLL
Are traditional cytotoxic chemotherapies becoming a thing of the past? This study in the Journal of Clinical Oncology shows a move toward targeted agents, as a combination of obinutuzumab, ibrutinib, and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Hematology November 9th 2020
How I Treat Relapsed Acute Lymphoblastic Leukemia in the Pediatric Population
In the past decade, several promising immunotherapies have been developed, changing the treatment landscape for children with relapsed acute lymphoblastic leukemia (ALL). These advances in treatment offer real promise for less toxic and more effective therapy for children. In this article from Blood, the authors present several cases highlighting contemporary treatment decision-making.
Hematology October 19th 2020